Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma

Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A. Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha

Research output: Contribution to journalArticle

Abstract

PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC. Materials and Methods: From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus. RESULTS: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]). CONCLUSION: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

Original languageEnglish
Pages (from-to)1578-1588
Number of pages11
JournalCancer research and treatment : official journal of Korean Cancer Association
Volume51
Issue number4
DOIs
Publication statusPublished - 2019 Oct 1

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Confidence Intervals
Survival
Nephrectomy
temsirolimus
Histology
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, Jii Bum ; Park, Hyung Soon ; Park, Sejung ; Lee, Hyo Jin ; Kwon, Kyung A. ; Choi, Young Jin ; Kim, Yu Jung ; Nam, Chung Mo ; Cho, Nam Hoon ; Kang, Beodeul ; Chung, Hyun Cheol ; Rha, Sun Young. / Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. In: Cancer research and treatment : official journal of Korean Cancer Association. 2019 ; Vol. 51, No. 4. pp. 1578-1588.
@article{a679e49c2c814789af84feea321fdc29,
title = "Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma",
abstract = "PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of na{\"i}ve Asian patients with metastatic/recurrent nccRCC. Materials and Methods: From January 2008 to July 2017, data of treatment-na{\"i}ve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus. RESULTS: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54{\%}) were papillary type, and other histology subtypes included 11 chromophobes (25{\%}), two collecting ducts (5{\%}), one Xp11.2 translocation (2{\%}), and six others (14{\%}). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11{\%} and disease control rate was 83{\%}. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95{\%} confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95{\%} CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95{\%} CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95{\%} CI, 1.23 to 6.56; p=0.015]). CONCLUSION: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.",
author = "Lee, {Jii Bum} and Park, {Hyung Soon} and Sejung Park and Lee, {Hyo Jin} and Kwon, {Kyung A.} and Choi, {Young Jin} and Kim, {Yu Jung} and Nam, {Chung Mo} and Cho, {Nam Hoon} and Beodeul Kang and Chung, {Hyun Cheol} and Rha, {Sun Young}",
year = "2019",
month = "10",
day = "1",
doi = "10.4143/crt.2018.671",
language = "English",
volume = "51",
pages = "1578--1588",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. / Lee, Jii Bum; Park, Hyung Soon; Park, Sejung; Lee, Hyo Jin; Kwon, Kyung A.; Choi, Young Jin; Kim, Yu Jung; Nam, Chung Mo; Cho, Nam Hoon; Kang, Beodeul; Chung, Hyun Cheol; Rha, Sun Young.

In: Cancer research and treatment : official journal of Korean Cancer Association, Vol. 51, No. 4, 01.10.2019, p. 1578-1588.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma

AU - Lee, Jii Bum

AU - Park, Hyung Soon

AU - Park, Sejung

AU - Lee, Hyo Jin

AU - Kwon, Kyung A.

AU - Choi, Young Jin

AU - Kim, Yu Jung

AU - Nam, Chung Mo

AU - Cho, Nam Hoon

AU - Kang, Beodeul

AU - Chung, Hyun Cheol

AU - Rha, Sun Young

PY - 2019/10/1

Y1 - 2019/10/1

N2 - PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC. Materials and Methods: From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus. RESULTS: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]). CONCLUSION: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

AB - PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC. Materials and Methods: From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus. RESULTS: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]). CONCLUSION: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85073183072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073183072&partnerID=8YFLogxK

U2 - 10.4143/crt.2018.671

DO - 10.4143/crt.2018.671

M3 - Article

C2 - 30999721

AN - SCOPUS:85073183072

VL - 51

SP - 1578

EP - 1588

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -